Cooper Companies price target lowered to $99 from $100 at Needham

Needham lowered the firm’s price target on Cooper Companies (COO) to $99 from $100 and keeps a Buy rating on the shares. Ahead of Sebela’s mid-2026 Miudella launch, the firm spoke to a couple of OB/GYNs to learn how it might impact their utilization of COO’s Paragard, and the doctors on average expect Miudella to take up to 5% of their total Paragard volume, which could increase if Miudella’s ongoing study results in a longer-term label, the analyst tells investors in a research note. Needham estimates Cooper could face up to 90 bps of EPS pressure in FY27 from Paragard competition.